Skip to main content
OpenTrials
Completed

NCT Number: NCT04316884

Mechanisms for Organ Dysfunction in Covid-19

The study aims to investigate organ dysfunction and biomarkers in patients with suspected or verified COVID-19 during intensive care at Uppsala University Hospital.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

COVID-19 Acute Kidney Injury Acute Respiratory Distress Syndrome Coronaviridae Infections Coronavirus Infections Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Infections Inflammation Kidney Diseases Lung Diseases Male Urogenital Diseases Multiple Organ Failure Nidovirales Infections Organ Dysfunction Syndrome Sepsis Organ Dysfunction Syndrome, Multiple Pathologic Processes Pathological Conditions, Signs and Symptoms Pneumonia Pneumonia, Viral RNA Virus Infections Renal Insufficiency Respiration Disorders Respiratory Distress Syndrome Respiratory Tract Diseases Respiratory Tract Infections Sepsis Septic Shock Shock Shock, Septic Systemic Inflammatory Response Syndrome Toxemia Urogenital Diseases Urologic Diseases Virus Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Uppsala University Hospital

Uppsala, Uppsala County, 75185, Sweden

About this study

Consenting patients with suspected or verified SARS-COV-2 infection, COVID-19, will undergo daily blood, urine and sputum sampling during their stay in intensive care. Data on organ dysfunction will be collected through the electronic patient journal and electronic patient data management system. The collected samples will be analysed for a panel of potential biomarkers that will be correlated to organ dysfunction and clinical outcome.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Admitted to intensive care
  • suspected or verified COVID-19

Exclusion criteria

  • Pregnancy or breastfeeding
  • Under-age

Treatment and study plan

Primary outcomes

  1. Acute Kidney Injury

    Time frame: During Intensive Care, an estimated average of 10 days.

    KDIGO AKI score

Secondary outcomes

  1. ARDS

    Time frame: During intensive care, an estimated average of 10 days.

    Acute Respiratory Distress Syndrome yes/no

  2. 30 day mortality

    Time frame: 30 days

    Death within 30 days of ICU admission

  3. 1 year mortality

    Time frame: 1 year

    Death within 1 year of ICU admission

  4. Chronic Kidney Disease

    Time frame: 60 days and 1 year after ICU admission

    Development of Chronic Kidney Disease

  5. SOFA-score

    Time frame: During Intensive Care, an estimated average of 10 days.

    Sequential Organ Failure Score as a continuous variable

  6. Thromboembolic events

    Time frame: During intensive care

    Occurence of thrombosis and/or embolous

  7. ICUAW

    Time frame: During intensive care or after intensive care

    Intensive care acquired weakness

Sponsors and collaborators

Lead sponsor

Uppsala University

Other

Registry information

Official study title

Uppsala Intensive Care Study of Mechanisms for Organ Dysfunction in Covid-19

Acronym: UMODCOVID19

Important dates

Study start
2020
Primary completion
2025
Study completion
2025
First posted
Mar 20, 2020
Registry last updated
Jan 12, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.